PLYMOUTH, Minn., Aug. 11, 2015 /PRNewswire/ -- Monteris Medical today announced that it has appointed James Reinstein to the company's Board of Directors.
"Mr. Reinstein has an exceptional track record in the medical device industry and we are confident that his decades of business leadership will provide invaluable expertise and strategic direction to the Monteris Medical Board of Directors and leadership team," said John Schellhorn, President and CEO of Monteris Medical. "His demonstrated success in commercializing high technology medical devices and deep experience in the fields of neurosurgery and neurology will be extremely valuable for our company as we navigate this period of rapid growth."
Most recently, Mr. Reinstein served as President and CEO of Aptus Endosystems, a medical device company focused on developing advanced technology for endovascular aneurysm repair, where he managed the successful acquisition of the company by Medtronic plc. Previously, he served as Executive Vice President and Chief Commercial Officer at Cyberonics, a neuromodulation company developing novel treatment options for patients with epilepsy, depression and chronic heart failure. During his tenure, he led the development of the company's strategic direction and enabled its commercial turnaround by growing revenues two-fold.
Mr. Reinstein also held global leadership roles of increasing responsibility at Boston Scientific, where during a nearly two decade tenure he built and managed successful operational teams in Latin America and Asia. Prior to these roles, he served in sales and sales management positions at Procter and Gamble.
Mr. Reinstein holds a Bachelor's Degree in Business Administration from Terry College of Business at the University of Georgia in Athens and is currently a General Partner at Palo Alto Medtech Advisors and sits on the board of directors at two publicly traded medical device companies.
"Monteris Medical is uniquely positioned to treat patients diagnosed with neurological diseases and intracranial lesions," said Mr. Reinstein. "With a growing customer base, I am confident that the company is going to continue its success and look forward to working with the Monteris Medical leadership team and other board members to help fulfill the company's mission and goal of treating and improving the quality of life of patients diagnosed with neurological disorders."
The company also announced that Gary Bantle, Partner with the BDC Capital Healthcare Fund, and one of the earliest investors in Monteris Medical, will be stepping down from the Board of Directors effective immediately.
"We are deeply appreciative of all that Mr. Bantle has accomplished as a member of the board, and would not be in our current position had it not been for his diligent efforts and leadership acumen," added Schellhorn. "We thank him for his commitment to Monteris Medical and the patients we serve."
About the NeuroBlate System®
The NeuroBlate System is FDA-cleared to ablate, necrotize or coagulate soft tissue encountered in the discipline of neurosurgery through the application of laser thermotherapy. NeuroBlate is a tool (as opposed to a "treatment") and is not intended to treat any specific disease. Physicians should use their clinical judgment and experience when deciding whether to use NeuroBlate.
Since it received clearance from the U.S. Food and Drug Administration (FDA) in April 2013, the NeuroBlate System has been adopted for use in more than 22 leading institutions across the country including Cleveland Clinic, UC San Diego Health System, Barnes Jewish Hospital, Washington University and Yale New Haven Hospital. Monteris Medical supports the installation of new systems with comprehensive hands-on training and ongoing technical support.
Full prescribing information for the NeuroBlate System is available at www.monteris.com.
Monteris Medical is a privately held company developing innovative MRI-guided, laser-based brain lesion therapy. Monteris Medical markets the NeuroBlate® System, a neurosurgical ablation device providing controlled therapy for difficult-to-treat brain lesions. Monteris also offers the AXiiiS® Stereotactic Miniframe; a single use platform for image-guided, stereotactic brain biopsy; and the AtamA™ Stabilization System for MRI-guided neurosurgical procedures requiring head fixation.
For more information on Monteris Medical please visit www.monteris.com.
SOURCE Monteris Medical